Slide 1: The Transplant Company - Earnings Presentation Q3 2022
The Transplant Company™ Focused on improving care across the entire transplant patient journey Leslie M, Kidney Transplant Recipient Earnings Presentation Q3 2022
Slide 2: Safe Harbor Statement
Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements, including statements with respect to expectations regarding CareDx’s upcoming milestones, vision and 2022 revenue guidance. All statements other than statements of historical fact contained
Slide 3: Our Vision, Our Mission
Our Vision The leading partner for the transplant ecosystem Our Mission We are committed to improving long-term outcomes by providing innovative solutions throughout the entire transplant patient journey
Slide 4: Q3 Earnings: Key Topics for Discussion
Q3 Earnings: Key Topics for Discussion • Differentiated financial profile • Driving future growth through the 3 C’s – Catalysts, Collections, Coverage • Building leadership in the transplant ecosystem 4
Slide 5: Q3 Financial and Operational Highlights
Q3 Financial and Operational Highlights Gross Volume Balance Sheet1 Revenue Profitability2,3 Margin2 Growth $291M Cash & 64% GAAP 46,500 Tests $79.4M Net loss equivalents 67% Adjusted ($16.9M) Up 3% Up 5% y/y No near-term 74% Testing sequentially Adjusted cash needs services2 and 15% y/y EBITDA ($2.
Slide 6: Kidney, Heart and Lung Transplant Volume Trends
Kidney, Heart and Lung Transplant Volume Trends Quarterly Transplant Volumes Transplant Volume % Growth – Quarter-over-Quarter 9000 20% Extended Recovery 3Q22 7976 15% 14% 8000 7870 Growth 7568 Slowdown 7357 7119 7118 10% 6977 7000 6% 5% 4% 6000 0% 0% -1% 5000 -3% -5% -8% 4000 -10% 1Q21 2Q21 3Q21 4Q
Slide 7: Extending Leadership in Transplant
Extending Leadership in Transplant Strong Progress Across All Organs Heart Testing Services Kidney Testing Services Lung Testing Services Launched 2005 Launched 2017 Launched Q4 2021 >90% Center >75% Center 60% Center penetration penetration penetration >95% HeartCare >100 Protocols >2,000 Tests att
Slide 8: Upcoming Growth Drivers – Catalysts, Collections, Coverage
Upcoming Growth Drivers – Catalysts, Collections, Coverage Pipeline Improving Increased Catalysts Collections Coverage • AlloMap Kidney Launch • Increase Medicare • cfDNA in ISHLT Guidelines • UroMap Submission to Advantage collection • AlloSure Lung CMS CMS and eventual launch efficiency • AlloMap
Slide 9: ASP on Reimbursed Tests
ASP on Reimbursed Tests All Paid Test ASP Trend (Testing Qtr) $3,000 FLAT $2,000 $1,000 $- Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 9 Source: data on file as of 9/30/22
Slide 10: Upcoming Growth Drivers – Catalysts, Collections, Coverage
Upcoming Growth Drivers – Catalysts, Collections, Coverage Pipeline Improving Increased Catalysts Collections Coverage • AlloMap Kidney Launch • Increase Medicare • cfDNA in ISHLT Guidelines • UroMap Submission to Advantage collection • AlloSure Lung CMS CMS and eventual launch efficiency • AlloMap
Slide 11: Our Vision: The Leader in The Transplant Ecosystem
Our Vision: The Leader in The Transplant Ecosystem Leadership across the patient journey Post Medication Quality Transplant NGS Electronic Transplant Transplant Discharge & focused App HLA Medical Patient Biomarkers Analytics Typing Records Referrals CareDx is CareDx is CareDx is CareDx is CareDx is
Slide 12: Q3 Financial and Operational Highlights
Q3 Financial and Operational Highlights Gross Volume Balance Sheet1 Revenue Profitability2,3 Margin2 Growth $291M Cash & 64% GAAP 46,500 Tests $79.4M Net loss equivalents 67% Adjusted ($16.9M) Up 3% Up 5% y/y No near-term 74% Testing sequentially Adjusted cash needs services1 and 15% y/y EBITDA ($2.
Slide 13: ASP on Reimbursed Tests
ASP on Reimbursed Tests All Paid Test ASP Trend (Testing Qtr) $3,000 FLAT $2,000 $1,000 $- Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 13
Slide 14: Our Vision, Our Mission
Our Vision The leading partner for the transplant ecosystem Our Mission We are committed to improving long-term outcomes by providing innovative solutions throughout the entire transplant patient journey
Slide 15: CareDx: Your Partner in Transplant Care
é Care Dx: Your Partner in Transplant Care 1s é CareDx
Slide 16: Appendix
Appendix 16 é CareDx:
Slide 17: Reconciliation of Non-GAAP Gross Margin
Reconciliation of Non-GAAP Gross Margin FY 2018 FY 2019 FY 2020 FY 2021 Q1 2022 Q2 2022 Q3 2022 in Millions (except %) Revenue 76.6 127.1 192.2 296.4 79.4 80.6 79.4 GAAP Cost of Revenue 33.0 45.5 63.1 97.4 26.9 27.5 28.3 Stock-based compensation expense (0.8) (2.2) (2.3) (3.7) (0.4) (1.4) (1.1) Acqu
Slide 18: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA in Millions FY 2018 FY 2019 FY 2020 FY 2021 Q1 2022 Q2 2022 Q3 2022 GAAP Net Loss (46.8) (22.0) (18.7) (30.7) (19.6) (21.7) (16.9) Stock-based compensation expense 7.1 22.4 23.4 36.1 10.6 12.6 11.2 Impairments & Write-downs - 0.2 - 2.4 - - 0.8 Unrealized gain on inv